Disease should be rare. Diagnosis shouldn't.

That’s the future we’re building at GeneDx.

We provide answers, so you can focus on care

Find the right diagnosis the first time.
Whole genome and exome testing offer a complete view of a patient’s genetic makeup and have a superior diagnostic yield to multi-gene panels. Additionally, more and more professional society guidelines support exome and genome testing as a first line test, particularly for epilepsy, intellectual disability/developmental delay, and congenital abnormalities. Starting complex disease patients with genome or exome testing means getting them to a diagnosis faster and saving patients and families years of unnecessary testing, heartache, and stress.
More accurate information means more effective treatment plans.
Our unique ability to analyze genomic information alongside comprehensive clinical datasets means patients are provided with an incredibly precise diagnosis.This enables patients to get the exact care they need, including connecting them to appropriate clinical trials or developing specialized care plans.
Science backed by support.
We are here for you and your patients throughout the entire testing process, from placing orders to interpreting results. Our dedicated team of genetic counselors provides peer-to-peer support as well as pre- and post-test counseling services. Also, our billing experts work with families on flexible and affordable payment plans so patients can get the care they need. With comprehensive care from start to finish, we offer more than just a test result.


One test. Big picture. Brighter futures.

Our mission is to deliver personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery.



At GeneDx, we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis.

Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers.

Our state-of-the-art interpretation platform, paired with our robust data set, make us the go-to lab when doctors need diagnoses for children with both rare diseases and common conditions.


Latest news

GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
April 29, 2024

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2024.


GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
April 23, 2024

The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine.


GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
April 4, 2024

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024.